Rajan Shobana, Deogaonkar Milind, Kaw Roop, Nada Eman Ms, Hernandez Adrian V, Ebrahim Zeyd, Avitsian Rafi
Department of General Anesthesiology, Anesthesiology Institute, Cleveland Clinic, 9500 Euclid Avenue, E-31, Cleveland, OH 44195, USA.
Department of Neurosurgery, Center for Neuromodulation, Ohio State University Medical Center, Columbus, OH, USA.
J Clin Neurosci. 2014 Oct;21(10):1790-5. doi: 10.1016/j.jocn.2014.04.005. Epub 2014 Jun 7.
Hypertension is common in deep brain stimulator (DBS) placement predisposing to intracranial hemorrhage. This retrospective review evaluates factors predicting incremental antihypertensive use intraoperatively. Medical records of Parkinson's disease (PD) patients undergoing DBS procedure between 2008-2011 were reviewed after Institutional Review Board approval. Anesthesia medication, preoperative levodopa dose, age, preoperative use of antihypertensive medications, diabetes mellitus, anxiety, motor part of the Unified Parkinson's Disease Rating Scale score and PD duration were collected. Univariate and multivariate analysis was done between each patient characteristic and the number of antihypertensive boluses. From the 136 patients included 60 were hypertensive, of whom 32 were on angiotensin converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB), told to hold on the morning of surgery. Antihypertensive medications were given to 130 patients intraoperatively. Age (relative risk [RR] 1.01; 95% confidence interval [CI] 1.00-1.02; p=0.005), high Joint National Committee (JNC) class (p<0.0001), diabetes mellitus (RR 1.4; 95%CI 1.2-17; p<0.0001) and duration of PD >10 years (RR 1.2; 95%CI 1.1-1.3; p=0.001) were independent predictors for antihypertensive use. No difference was noted in the mean dose of levodopa (p=0.1) and levodopa equivalent dose (p=0.4) between the low (I/II) and high severity (III/IV) JNC groups. Addition of dexmedetomidine to propofol did not influence antihypertensive boluses required (p=0.38). Intraoperative hypertension during DBS surgery is associated with higher age group, hypertensive, diabetic patients and longer duration of PD. Withholding ACEI or ARB is an independent predictor of hypertension requiring more aggressive therapy. Levodopa withdrawal and choice of anesthetic agent is not associated with higher intraoperative antihypertensive medications.
高血压在深部脑刺激器(DBS)植入术中很常见,易引发颅内出血。本回顾性研究评估术中预测递增性抗高血压药物使用的因素。在获得机构审查委员会批准后,对2008年至2011年间接受DBS手术的帕金森病(PD)患者的病历进行了回顾。收集了麻醉药物、术前左旋多巴剂量、年龄、术前抗高血压药物使用情况、糖尿病、焦虑症、统一帕金森病评定量表运动部分评分以及PD病程。对每个患者特征与抗高血压推注次数进行了单因素和多因素分析。在纳入的136例患者中,60例为高血压患者,其中32例服用血管紧张素转换酶抑制剂(ACEI)或血管紧张素受体阻滞剂(ARB),被告知在手术当天早晨停药。术中130例患者接受了抗高血压药物治疗。年龄(相对危险度[RR]1.01;95%置信区间[CI]1.00 - 1.02;p = 0.005)、高血压分级高(p < 0.0001)、糖尿病(RR 1.4;95%CI 1.2 - 1.7;p < 0.0001)以及PD病程>10年(RR 1.2;95%CI 1.1 - 1.3;p = 0.001)是抗高血压药物使用的独立预测因素。低(I/II)和高严重程度(III/IV)高血压分级组之间左旋多巴平均剂量(p = 0.1)和左旋多巴等效剂量(p = 0.4)无差异。在丙泊酚中添加右美托咪定不影响所需的抗高血压推注次数(p = 0.38)。DBS手术期间的术中高血压与年龄较大、高血压、糖尿病患者以及较长的PD病程相关。停用ACEI或ARB是需要更积极治疗的高血压的独立预测因素。停用左旋多巴和麻醉剂的选择与术中更高的抗高血压药物使用无关。